Vivani Medical, Inc. Overview
Pro stress-test →Vivani Medical is a clinical-stage biopharmaceutical company developing miniaturized and subdermal drug implants using its proprietary NanoPortal implant technology to address chronic diseases and medication non-adherence. The company is pursuing a pivotal opportunity in obesity/weight management by developing ultra long-acting implants that deliver therapy for six months or longer with a single administration.
Strategic Profile
Pro stress-test →Formed in August 2022 through a merger of Second Sight Medical Products and Nano Precision Medical, Vivani inherited neurostimulation assets and NPM's NanoPortal drug implant technology, with a strategic pivot to prioritize the Biopharm pipeline. The company announced the spin-off of Cortigent, its wholly-owned subsidiary developing brain implant devices with cutting-edge neuromodulation technology.
Competitive Landscape
Pro stress-test →Vivani's GLP-1 implant candidates aim to deliver the same active ingredients as market leaders like Ozempic, Trulicity, and Wegovy through an implant format. Competitors include established injectable GLP-1 providers (Novo Nordisk, Eli Lilly), long-acting GLP-1 formulations in development, and other implant-based delivery platforms targeting chronic disease adherence.
Industry Context
Vivani Medical, Inc. operates in Biopharmaceutical/Medical Devices - Drug Delivery Systems.
Key facts
Founded: 2022 · Headquarters: Alameda, CA, United States · Market cap: $78.2M